Media stories about Synergy Pharmaceuticals (NASDAQ:SGYP) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.7611946264886 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- After Hours Most Active for Nov 10, 2017 : F, SGYP, GE, RICE, BAC, AAPL, LC, CLF, MU, MDLZ, CELG, QQQ – Nasdaq (nasdaq.com)
- Synergy Pharmaceuticals: Momentum Ahead Of IBS-C Approval For Trulance – Seeking Alpha (seekingalpha.com)
- Synergy Pharmaceuticals, Inc. (SGYP) Short Interest Up 3.1% in October (americanbankingnews.com)
- Mind-blowing Stocks: Pandora Media, Inc. (NYSE:P), Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), B2Gold Corp … – The Stock Street (press release) (thestreetpoint.com)
- Beta Factor under Consideration – Synergy Pharmaceuticals Inc., (NASDAQ: SGYP) – Stock Watch (stocksnewstimes.com)
Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) traded down $0.25 during trading hours on Friday, hitting $2.72. 20,258,900 shares of the stock traded hands, compared to its average volume of 5,633,911. The company has a quick ratio of 2.07, a current ratio of 2.33 and a debt-to-equity ratio of 0.39. Synergy Pharmaceuticals has a twelve month low of $2.56 and a twelve month high of $7.15.
Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. The company had revenue of $5.01 million for the quarter, compared to analysts’ expectations of $4.53 million. During the same quarter in the prior year, the firm posted ($0.22) EPS. equities research analysts forecast that Synergy Pharmaceuticals will post -1.13 EPS for the current year.
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $11.00 price target on shares of Synergy Pharmaceuticals in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $9.00 price target on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. HC Wainwright set a $15.00 price target on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. Rodman & Renshaw decreased their price target on shares of Synergy Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, August 10th. Finally, Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating and set a $3.25 price target for the company in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. Synergy Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.39.
WARNING: “Synergy Pharmaceuticals (SGYP) Getting Somewhat Favorable News Coverage, Analysis Shows” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/11/synergy-pharmaceuticals-sgyp-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.